Wuxi Biologics Sees Revenue Growing 10% in 2023
Wall Street Journal
Wuxi Biologics has said that its operations remain normal, coming after shares of the Chinese contract drugmaker slid 24% and were halted in the wake of revised guidance.
https://www.wsj.com/articles/wuxi-biologics-sees-revenue-growing-10-in-2023-9b2f4b11